Reviva Pharmaceuticals Holdings, Inc. Research and Development Expense
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Research and Development Expense of $1.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Reviva Pharmaceuticals Holdings, Inc. research and development expense for the quarter ending 2026-06-30 was $1.39M, a 62.56% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. research and development expense for the quarter ending 2026-03-31 was $1.44M, a 65.11% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. research and development expense for the quarter ending 2025-12-31 was $1.74M, a 62.85% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. research and development expense for the quarter ending 2025-09-30 was $2.13M, a 68.92% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. research and development expense for fiscal 2025 was $11.71M, a 48.89% decline from fiscal 2024.
- Reviva Pharmaceuticals Holdings, Inc. research and development expense for fiscal 2024 was $22.91M, a 27.09% decline from fiscal 2023.
- Reviva Pharmaceuticals Holdings, Inc. research and development expense for fiscal 2023 was $31.42M, a 37.38% increase from fiscal 2022.
- Reviva Pharmaceuticals Holdings, Inc. research and development expense for fiscal 2022 was $22.87M, a 371.39% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 11 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.39M 10-Q · filed 2026-08-12 | $2.83M 10-Q · filed 2026-08-12 | $4.57M derived: sum of 3 quarters · filed 2026-08-12 | $6.70M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2026-03-31 | $1.44M 10-Q · filed 2026-05-13 | $3.17M derived: sum of 2 quarters · filed 2026-05-13 | $5.31M derived: sum of 3 quarters · filed 2026-05-13 | $9.03M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.87M derived: sum of 2 quarters · filed 2026-03-30 | $7.60M derived: sum of 3 quarters · filed 2026-08-12 | $11.71M 10-K · filed 2026-03-30 | |||||
| 2025-09-30 | $2.13M 10-Q · filed 2025-11-13 | $5.86M derived: sum of 2 quarters · filed 2026-08-12 | $9.97M 10-Q · filed 2025-11-13 | $14.65M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-06-30 | $3.72M 10-Q · filed 2026-08-12 | $7.84M 10-Q · filed 2026-08-12 | $12.52M derived: sum of 3 quarters · filed 2026-08-12 | $19.38M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-03-31 | $4.11M 10-Q · filed 2026-05-13 | $8.79M derived: sum of 2 quarters · filed 2026-05-13 | $15.65M derived: sum of 3 quarters · filed 2026-05-13 | $21.24M derived: sum of 4 quarters · filed 2026-05-13 | |||||
| 2024-12-31 | $4.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $11.54M derived: sum of 2 quarters · filed 2026-03-30 | $17.12M derived: sum of 3 quarters · filed 2026-03-30 | $22.91M 10-K · filed 2026-03-30 | |||||
| 2024-09-30 | $6.86M 10-Q · filed 2025-11-13 | $12.44M derived: sum of 2 quarters · filed 2025-11-13 | $18.23M 10-Q · filed 2025-11-13 | $26.33M derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | $5.58M 10-Q · filed 2025-08-14 | $11.37M 10-Q · filed 2025-08-14 | $19.48M derived: sum of 3 quarters · filed 2025-08-14 | $29.05M derived: sum of 4 quarters · filed 2025-08-14 | |||||
| 2024-03-31 | $5.78M 10-Q · filed 2025-05-15 | $13.89M derived: sum of 2 quarters · filed 2025-05-15 | $23.46M derived: sum of 3 quarters · filed 2025-05-15 | $31.72M derived: sum of 4 quarters · filed 2025-05-15 | |||||
| 2023-12-31 | $8.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-03 | $17.68M derived: sum of 2 quarters · filed 2025-04-03 | $25.94M derived: sum of 3 quarters · filed 2025-04-03 | $31.42M 10-K · filed 2025-04-03 | |||||
| 2023-09-30 | $9.57M 10-Q · filed 2024-11-14 | $8.72M 10-Q · filed 2023-11-14 | $17.83M derived: sum of 2 quarters · filed 2024-11-14 | $23.31M 10-Q · filed 2024-11-14 | $22.94M 10-Q · filed 2023-11-14 | $30.73M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $8.26M 10-Q · filed 2024-08-14 | $8.99M 10-Q · filed 2023-08-14 | $13.74M 10-Q · filed 2024-08-14 | $14.23M 10-Q · filed 2023-08-14 | $21.16M derived: sum of 3 quarters · filed 2024-08-14 | $25.40M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $5.48M 10-Q · filed 2024-05-14 | $5.23M 10-Q · filed 2023-05-15 | $12.90M derived: sum of 2 quarters · filed 2024-05-14 | $17.14M derived: sum of 3 quarters · filed 2024-05-14 | $21.66M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $7.42M derived: 10-K 12 month − 10-K 9 month · filed 2024-04-15 | $11.66M derived: sum of 2 quarters · filed 2024-04-15 | $16.17M derived: sum of 3 quarters · filed 2024-04-15 | $22.87M 10-K · filed 2024-04-15 | $18.95M 10-K · filed 2023-03-30 | ||||
| 2022-09-30 | $4.24M 10-K · filed 2024-04-15 | $2.31M 10-Q · filed 2022-11-14 | $8.76M derived: sum of 2 quarters · filed 2024-04-15 | $15.45M 10-K · filed 2024-04-15 | $12.65M 10-Q · filed 2022-11-14 | $17.25M derived: sum of 4 quarters · filed 2024-04-15 | |||
| 2022-06-30 | $4.51M 10-Q · filed 2023-08-14 | $10.34M 10-Q · filed 2023-08-14 | $13.01M derived: sum of 3 quarters · filed 2023-08-14 | $14.43M derived: sum of 4 quarters · filed 2023-08-14 | |||||
| 2022-03-31 | $5.83M 10-Q · filed 2023-05-15 | $8.49M derived: sum of 2 quarters · filed 2023-05-15 | $9.92M derived: sum of 3 quarters · filed 2023-05-15 | $10.29M derived: sum of 4 quarters · filed 2023-05-15 | |||||
| 2021-12-31 | $2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $4.09M derived: sum of 2 quarters · filed 2023-03-30 | $4.46M derived: sum of 3 quarters · filed 2023-03-30 | $4.85M 10-K · filed 2023-03-30 | |||||
| 2021-12-13 | $4.85M 10-K · filed 2022-03-15 | ||||||||
| 2021-09-30 | $1.42M 10-Q · filed 2022-11-14 | $1.80M derived: sum of 2 quarters · filed 2022-11-14 | $2.19M 10-Q · filed 2022-11-14 | $2.19M derived: sum of 4 quarters · filed 2022-11-14 | |||||
| 2021-06-30 | $374.33K 10-Q · filed 2022-08-15 | $765.49K 10-Q · filed 2022-08-15 | $765.49K derived: sum of 3 quarters · filed 2022-08-15 | $766.45K derived: sum of 4 quarters · filed 2022-08-15 | |||||
| 2021-03-31 | $391.16K 10-Q · filed 2022-05-16 | $391.16K derived: sum of 2 quarters · filed 2022-05-16 | $392.12K derived: sum of 3 quarters · filed 2022-05-16 | $428.59K derived: sum of 4 quarters · filed 2022-05-16 | |||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $955.00 derived: sum of 2 quarters · filed 2022-03-15 | $37.43K derived: sum of 3 quarters · filed 2022-03-15 | $295.15K 10-K · filed 2022-03-15 | |||||
| 2020-09-30 | $955.00 10-Q · filed 2021-11-15 | $37.43K derived: sum of 2 quarters · filed 2021-11-15 | $295.15K 10-Q · filed 2021-11-15 | ||||||
| 2020-06-30 | $36.47K 10-Q · filed 2021-08-16 | $294.19K 10-Q · filed 2021-08-16 | |||||||
| 2020-03-31 | $271.25K 10-Q · filed 2021-05-17 | ||||||||
| 2019-12-31 | $195.74K 10-K/A · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |